拓新药业
(301089)
| 流通市值：29.26亿 | | | 总市值：40.70亿 |
| 流通股本：9097.63万 | | | 总股本：1.27亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 271,553,589.37 | 181,899,752.24 | 96,994,677.03 | 421,694,066.41 |
| 营业收入 | 271,553,589.37 | 181,899,752.24 | 96,994,677.03 | 421,694,066.41 |
| 二、营业总成本 | 309,371,817.19 | 202,283,727.81 | 104,540,673.11 | 444,664,721.27 |
| 营业成本 | 191,822,036.06 | 125,126,680.21 | 67,258,386.01 | 295,746,607.74 |
| 税金及附加 | 5,745,761.95 | 3,942,785.86 | 2,179,935.8 | 7,873,037.63 |
| 销售费用 | 7,918,604.54 | 5,324,403.79 | 2,421,618.47 | 12,953,053.38 |
| 管理费用 | 72,785,755.57 | 46,993,948.07 | 23,695,005.3 | 91,465,623.34 |
| 研发费用 | 31,165,593.91 | 20,997,456.2 | 9,124,533.9 | 40,046,804.25 |
| 财务费用 | -65,934.84 | -101,546.32 | -138,806.37 | -3,420,405.07 |
| 其中:利息费用 | 119,936.77 | 81,963.7 | 40,784.94 | 53,515.72 |
| 其中:利息收入 | 698,353.03 | 267,986.67 | 114,070.34 | 2,636,405.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 276,136.12 | 755,247.22 | 361,471.24 | 875,756.43 |
| 加:投资收益 | 3,035,838.61 | 1,703,047.95 | 1,011,509.12 | 677,321.82 |
| 资产处置收益 | - | - | - | -5,674.6 |
| 资产减值损失(新) | -7,316,298.7 | -7,316,298.7 | - | -10,678,437.92 |
| 信用减值损失(新) | 904,823.12 | 983,104.68 | 373,088.18 | -4,097,878.88 |
| 其他收益 | 4,559,553.75 | 3,203,057.75 | 2,065,448.22 | 12,481,393.24 |
| 四、营业利润 | -36,358,174.92 | -21,055,816.67 | -3,734,479.32 | -23,718,174.77 |
| 加:营业外收入 | 363,833.31 | 73,868.14 | 19,762.83 | 195,370.83 |
| 减:营业外支出 | 515,280.55 | 449,382.37 | 253,554.04 | 4,209,682.55 |
| 五、利润总额 | -36,509,622.16 | -21,431,330.9 | -3,968,270.53 | -27,732,486.49 |
| 减:所得税费用 | -6,348,545.25 | -3,150,781.35 | -403,529.84 | -7,847,617.57 |
| 六、净利润 | -30,161,076.91 | -18,280,549.55 | -3,564,740.69 | -19,884,868.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -30,161,076.91 | -18,280,549.55 | -3,564,740.69 | -19,884,868.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -30,161,076.91 | -18,280,549.55 | -3,564,740.69 | -19,884,868.92 |
| 扣除非经常损益后的净利润 | -35,942,839.18 | -22,207,618.53 | -5,952,687.74 | -27,255,389.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.24 | -0.14 | -0.03 | -0.16 |
| (二)稀释每股收益 | -0.24 | -0.14 | -0.03 | -0.16 |
| 八、其他综合收益 | - | - | - | 769,185.76 |
| 归属于母公司股东的其他综合收益 | - | - | - | 769,185.76 |
| 九、综合收益总额 | -30,161,076.91 | -18,280,549.55 | -3,564,740.69 | -19,115,683.16 |
| 归属于母公司股东的综合收益总额 | -30,161,076.91 | -18,280,549.55 | -3,564,740.69 | -19,115,683.16 |
| 公告日期 | 2025-10-29 | 2025-08-27 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |